

ProKnow cloud-based system for radiotherapy data storage, communication and management: early value assessment

HealthTech guidance
Published: 28 March 2023
Last updated: 14 March 2024

www.nice.org.uk/guidance/htg664

Your responsibility

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account, and specifically any special arrangements relating to the introduction of new interventional procedures. The guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the [Yellow Card Scheme](#).

Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties. Providers should ensure that governance structures are in place to review, authorise and monitor the introduction of new devices and procedures.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should [assess and reduce the environmental impact of implementing NICE recommendations wherever possible](#).

Contents

1 Recommendations	4
2 Potential value	8
3 The technology	9
Technology	9
Comparator	9
Current use of ProKnow	10
4 Committee discussion	11
Unmet need	11
Further evidence	11
Clinical effectiveness	12
Costs and resource use	12
Evidence gap overview	13
5 Evidence generation recommendations	15
6 Committee members and NICE project team	16
Committee members	16
NICE project team	16
Update information	17

This guidance replaces HTE5.

1 Recommendations

- 1.1 ProKnow can be used while further evidence is generated. This includes use of all 3 ProKnow modules:
 - ProKnow DS – a database used for importing, analysing and storing patient data
 - ProKnow CA – a contouring accuracy tool to practise, study and improve anatomical contouring
 - ProKnow PS – a platform for creating and comparing radiotherapy treatment plans.

Potential benefits of early access

- **Access:** In March 2022, NHS England commissioned a pilot of ProKnow (including all 3 modules) across 49 specialist cancer centres with funding provided until March 2025 as part of the Radiotherapy Transformation Programme. The programme aims to improve quality and reduce variability in radiotherapy services across the NHS.
- **System benefit:** Early evidence suggests that ProKnow may help to increase the number of treatment plans that are peer reviewed, either within or between centres. This could reduce variation in practice and improve knowledge sharing between healthcare professionals. This could lead to increased adherence to national guidance and local peer review protocols, and to improvements in the overall quality of radiotherapy treatment plans. ProKnow also offers clinical oncology training tools, which can be used to improve staff training in radiotherapy treatment planning.
- **Equality:** ProKnow enables clinicians to access and peer review radiotherapy treatment plans remotely, so it may particularly benefit smaller centres by providing access to clinical oncologists from other centres and improve care across the UK. ProKnow may also provide greater benefit in cases relating to rare or complex cancers, when there is more need for plans to be peer reviewed.

Considerations for early access

- **Information governance:** Adverse events relating to patient care are not expected when using ProKnow, but potential risks include confidentiality breaches or issues accessing or retrieving data. So, all centres should ensure they have appropriate IT infrastructure and information governance protocols in place.
- **Outcomes:** ProKnow is not expected to directly affect patient outcomes. How much ProKnow improves the quality of radiotherapy contours and treatment plans is likely to be difficult to quantify and attribute costs to. Surrogate outcome measures may be needed to quantify the quality of radiotherapy treatment plans.
- **Costs:** ProKnow may help to increase the number of treatment plans and contours that are peer reviewed and provide a place to document their quality

assurance, which may lead to benefits for people having radiotherapy. Increased peer review is likely to increase staff time and costs, which should be considered in addition to the cost of purchasing ProKnow.

1.2 Further evidence should be generated on:

- the impact on quality assurance for radiotherapy treatment planning, including surrogate, qualitative, and quantitative measures such as:
 - changes to radiotherapy treatment plans
 - dose prescription changes
 - dose volume distributions
 - scorecards.
- healthcare professionals' experience of using ProKnow, including usability
- ease of retrieving and storing patient data
- radiotherapy treatment planning time (including difference in time to start of treatment)
- changes in the number of internal and external peer reviews
- the impact on staffing and treatment planning resources
- the impact on clinical oncology training for healthcare professionals who contribute to radiotherapy treatment planning
- the ability for data linkage to national registries (including change in the number of treatment plans added to national registries)
- changes in inequality of access.

Find out more in the evidence generation section of this guidance.

The evidence generation plan gives further information on the prioritised evidence gaps and outcomes, ongoing studies and potential real-world data sources. It includes how the

evidence gaps could be resolved through real-world evidence studies.

2 Potential value

- 2.1 ProKnow is a cloud-based system that can potentially help improve quality in radiotherapy by enabling the following:
- Remote peer review within and between centres. This could potentially lead to greater adherence to national guidance and local peer review protocols, and higher-quality radiotherapy treatment plans. The peer review process is intended to improve standardisation, reduce variation in practice and improve knowledge sharing between healthcare professionals involved in treatment planning.
 - Increased ease of storing and retrieving patient data for analysis. This could lead to reduced staff resources needed for data collection, for example by reducing staff needed to do audits to monitor peer review.
 - Reduced adverse events and costs associated with treatment planning errors.
 - Standardised scoring systems and analysis of multiple datasets. In some cases, this could lead to changes in treatment modality, doses or fractionation. An improved understanding of treatment could lead to changes in dosimetry thresholds in national guidance.
 - Training support using the ProKnow CA module. This could lead to improvements in contouring accuracy over time.

3 The technology

Technology

- 3.1 ProKnow is a system used in radiotherapy offering a cloud-based data repository, communication tools and analytics software. The technology is used for people having image-guided 3D planned radiotherapy, and allows centres to compare radiotherapy plans and collect images and dosimetric data. ProKnow can be used to view treatment plan information, visualise images and the structures they contain, and inspect dosimetric data, such as dose volume histograms and dose distributions. Custom treatment plan quality metrics can be extracted, such as data on local radiotherapy control, survivorship, and side effects. ProKnow allows teams to work together to mark the areas of interest on images, in a process known as contouring. This can be done from any computer without the need for a dedicated workstation, so it allows collaboration and peer review of treatment plans between centres that are using ProKnow. At present, ProKnow is not used for brachytherapy, radionuclide therapy or 4D datasets.

Comparator

- 3.2 The comparator is standard care, which varies across centres. Most radiotherapy departments have local radiotherapy protocols specifying the technique and dose for each tumour site. Treatment planning involves clinical oncologists, radiographers, dosimetrists and medical physicists, with the qualified clinical oncologist taking overall responsibility for planning and final sign-off. Peer review is an important step in treatment planning to ensure the proposed plan will deliver safe and effective treatment, and to identify issues that could affect quality of care. The peer review process is also intended to improve standardisation and reduce variation in practice, and improve knowledge sharing between healthcare professionals involved in treatment planning.

Current use of ProKnow

- 3.3 The [Royal College of Radiologists' \(RCR\) guidance on radiotherapy target volume definition and peer review \(2022\)](#) says that departments should have agreed radiotherapy protocols for each tumour subsite. These protocols should include target volume guidelines, be agreed by the departments working together, and should be standardised across operational delivery networks, as well as nationally or internationally if possible. There are several different methods, software and technologies used for peer review in NHS practice.
- 3.4 In March 2022, NHS England commissioned a pilot of ProKnow across 49 specialist cancer centres with funding provided until March 2025.

4 Committee discussion

Unmet need

- 4.1 There is a need to increase standardisation of radiotherapy treatment planning protocols across radiotherapy centres in the NHS. The clinical experts noted that peer review is done by clinical oncologists and physics and dosimetry leads using different methods, such as in person or using Microsoft Teams. But, when there is a shortage of staff to do peer reviews or a backlog in radiotherapy treatment planning, peer review may not take place. ProKnow could help address the large variation between centres through training, data collection, scorecards and linkage to national registries.
- 4.2 The clinical experts agreed that smaller centres with fewer radiotherapy staff have more difficulty allocating time for peer review, so they may benefit more from using a platform that allows upload of radiotherapy treatment plans for external review. For rare and complex cancers, when there may only be one specialist in a centre, ProKnow could allow communication with clinicians in other locations using a standardised format. The peer review function within ProKnow also does not need users to be online at the same time, so both clinicians do not need to be present during the peer review process, which would be the case for in-person or virtual meetings. The committee concluded that ProKnow may enable an increase in the number of radiotherapy treatment plans undergoing peer review, which would bring clinical practice more in line with guidelines from the Royal College of Radiologists.

Further evidence

- 4.3 Further evidence will be generated while ProKnow is in use to explore the impact of the technology on patient outcomes and radiotherapy treatment planning resources. The clinical experts noted that ProKnow is unlikely to have any direct effect on patient outcomes, but the technology may increase adherence to national guidelines and have a positive impact on clinical oncology training.

Additional efficiency-related metrics may also be collected to estimate the impact on staffing and resources. The committee concluded that ProKnow can be used for radiotherapy data storage, communication and management while further evidence is generated.

Clinical effectiveness

- 4.4 The evidence includes 8 service evaluations or audits of treatment plan quality and 4 service evaluations or audits assessing the use of ProKnow during training. Two were done exclusively in a UK or NHS population. The evidence highlights the versatility of ProKnow to enable data sharing, including radiotherapy treatment plans, and the tools it has to enable quality assurance and review. The evidence also shows the functionality of ProKnow as a training tool for treatment planning and contouring. The clinical experts said that this could improve clinicians' skills in radiotherapy treatment planning and reduce variability between clinicians. Future uses of ProKnow may include evaluation of artificial intelligence technologies for treatment planning and contouring. It could also be used to link data to national routine datasets to determine the impact of ProKnow on patient outcomes. But the committee noted that there is a lack of prospective and comparative evidence for ProKnow. This means that it is not possible to show the impact of ProKnow on treatment planning outcomes, quality assurance, or hospital resource use. The committee concluded that the evidence base is very limited for ProKnow. See the [assessment report on the NICE website](#) for full details of the clinical evidence.

Costs and resource use

- 4.5 The External Assessment Group (EAG) considered the costs and resources associated with ProKnow's use in the peer review process within the care pathway. The EAG identified the key parameters affecting the cost of ProKnow. They are the length of peer review activity and the cost of purchasing the technology, which is based on the number of linear accelerators and amount of data storage needed per year. The EAG also did a scenario analysis, in which they changed the length of peer review and the number of people ProKnow was used

for. A conceptual 1% increase in the proportion of plans being peer reviewed for 15 minutes, 30 minutes, and 45 minutes by a consultant oncologist would cost an additional £0.62, £1.23, and £1.85 per person, respectively.

- 4.6 The EAG was able to outline key cost parameters and do a scenario analysis to estimate the cost of ProKnow per year, but they noted that the broader staff and resource impact of introducing ProKnow into the process of radiotherapy treatment planning hasn't been quantified. ProKnow could increase the proportion of treatment plans undergoing peer review. This would incur an additional cost because of the increase in staff time needed to do peer review that was previously not done, but this activity could lead to improved patient outcomes. Any potential cost savings because of improved patient outcomes or more efficient resource use would also have to be included in an economic evaluation. The committee concluded that more data on these cost parameters is needed.

Evidence gap overview

- 4.7 The key evidence gaps relate to the care pathway and key outcomes. The committee concluded that the evidence is very limited, so evidence generation is needed to address the following key evidence gaps:
- There is large variation in peer review practice across the NHS, including the proportion of treatment contours and plans undergoing peer review, who does peer review, and the tools to support how peer review is done in the NHS. Additional work is needed to quantify this variation and the uncertainty associated with the costs of delivering standard care in radiotherapy treatment planning.
 - There is a lack of evidence to quantify the impact of ProKnow on patient outcomes. It is possible that increased peer review will lead to an improvement in the quality of radiotherapy treatment plans resulting in better patient outcomes, but this is difficult to quantify.
 - There is limited (qualitative or non-qualitative) evidence reporting on the usability or clinician user experience of ProKnow and the ease of retrieving or storing patient data.

- There is no comparative evidence or validated competency assessment exploring the impact of ProKnow on clinical oncology training.
- There is an evidence gap relating to adverse events in large case datasets, which could be addressed as part of the NHS England commissioned pilot of ProKnow. No publications reported adverse events specifically relating to the use of ProKnow. The EAG noted that adverse events relating to patient care would not be expected for the evidence included. But adverse events may relate to confidentiality breaches or issues accessing or retrieving data, which were not reported in the included publications.
- There is limited evidence available for the economic modelling. The EAG was able to outline key cost parameters and conduct a scenario analysis to estimate the cost of ProKnow per year. But it noted that further research is needed to quantify the broader staff and resource impact of introducing ProKnow into radiotherapy treatment planning. This should include any impact on overall radiotherapy treatment planning time.

5 Evidence generation recommendations

- 5.1 The committee recommended further evidence generation for the use of ProKnow. The committee considered that the key outcomes could be addressed through service evaluations associated with the commissioning of ProKnow across the NHS in England. Evidence generated as part of a large national evaluation would be reflective of practice in the NHS across the UK and is likely to be sufficient for future decision-making.
- 5.2 The key outcomes that were prioritised by the committee for evidence generation include:
- the impact of ProKnow on quality assurance for radiotherapy treatment planning
 - changes in the number of internal and external peer reviews
 - usability and ease of retrieving and storing patient data
 - radiotherapy treatment planning time
 - the impact on staffing and treatment planning resources
 - the impact on clinical oncology training
 - changes in inequality of access for patients.

6 Committee members and NICE project team

Committee members

This topic was considered by NICE's medical technologies advisory committee, which is a standing advisory committee of NICE.

Committee members are asked to declare any interests in the technology to be evaluated. If there is considered to be a conflict of interest, the member is excluded from participating further in that evaluation.

The minutes of the medical technologies advisory committee, which include the names of the members who attended and their declarations of interests, are posted on the NICE website.

NICE project team

Each medical technologies guidance topic is assigned to a team consisting of 1 or more health technology assessment analysts (who act as technical leads for the topic), a health technology assessment adviser and a project manager.

Farhaan Jamadar

Health technology assessment analyst

Kimberley Carter

Health technology assessment adviser

Elizabeth Islam and Harriet Wilson

Project managers

Update information

March 2024: The evidence generation plan gives further information on the prioritised evidence gaps and outcomes, ongoing studies and potential real-world data sources. It includes how the evidence gaps could be resolved through real-world evidence studies.

ISBN: 978-1-4731-5841-2